Sentence ID	Sentence
504	 PROTEIN1 beta protein (25-35) stimulation of PROTEIN2 A, C and D activities of LA-N-2 cells
505	[3H]Inositol prelabeled LA-N-2 cells were exposed to varying concentrations of PROTEIN1 from 20 to 125 micrograms/ml, and PROTEIN2 activation was measured
506	The effects of adrenergic, metabotropic amino acid and bombesin antagonists on the PROTEIN1 mediated stimulation of PROTEIN2 activity was investigated
507	Propranolol, a beta adrenergic antagonist, 7-chloro-kynurenic acid, a metabotropic amino acid antagonist, and [Tyr4-D-Phe12]bombesin, a bombesin antagonist, blunted the PROTEIN1 stimulation of PROTEIN2 activity in [3H]inositol prelabeled LA-N-2 cells
508	This suggests that PROTEIN1 beta protein activation of PROTEIN2 may be receptor mediated
509	The PROTEIN1 inhibitor U 71322 prevented the activation of PROTEIN by PROTEIN2 
510	The PROTEIN inhibitor U 71322 prevented the activation of PROTEIN1 by PROTEIN2 
511	The PROTEIN1 inhibitor U 71322 prevented the activation of PROTEIN2 by PROTEIN 
512	These results suggest that PROTEIN1 secretion and PROTEIN production in NT2N neurons are regulated by the muscarinic/ PROTEIN2 signal transduction pathway
513	These results suggest that PROTEIN secretion and PROTEIN1 production in NT2N neurons are regulated by the muscarinic/ PROTEIN2 signal transduction pathway
514	These results suggest that PROTEIN1 secretion and PROTEIN2 production in NT2N neurons are regulated by the muscarinic/ PROTEIN signal transduction pathway
515	Current interest in reducing heart disease risks by diet involves attention to total fat; saturated, monounsaturated, polyunsaturated and trans fatty acids, as well as dietary PROTEIN1 soluble fiber, salt, alcohol, antioxidants, dietary alterations causing homocysteinemia and other dietary constituents, such as PROTEIN2 compounds in some soy products
516	These data suggest that cAMP-dependent phosphorylation at a step involving GTP-binding protein/PLC coupling can exert a negative effect on the stimulation of PROTEIN1 formation by PROTEIN2 and thereby affect contraction/relaxation in the myometrium
517	Roles of GTP and PROTEIN1 in the potentiation of Ca(2+)-induced PROTEIN2 secretion by glucose in rat pancreatic islets
518	There was a 98% greater augmentation of PROTEIN1 secretion by 16.7 mM glucose (in the presence of diazoxide and 40 mM K+) in primed islets; however, the ability of high glucose to augment PROTEIN2 activity bore no relationship to the secretory response
519	MPA markedly inhibited PROTEIN1 in both conditions; however, PROTEIN2 secretion was only inhibited (by 46%) in primed islets
520	These data indicate that an adequate level of GTP is critical for glucose's potentiation of Ca(2+)-induced PROTEIN1 secretion in primed islets but that PROTEIN activation can clearly be dissociated from PROTEIN2 secretion and therefore cannot be the major cause of glucose's augmentation of Ca(2+)-induced PROTEIN secretion
521	These data indicate that an adequate level of GTP is critical for glucose's potentiation of Ca(2+)-induced PROTEIN secretion in primed islets but that PROTEIN1 activation can clearly be dissociated from PROTEIN2 secretion and therefore cannot be the major cause of glucose's augmentation of Ca(2+)-induced PROTEIN secretion
522	These data indicate that an adequate level of GTP is critical for glucose's potentiation of Ca(2+)-induced PROTEIN secretion in primed islets but that PROTEIN activation can clearly be dissociated from PROTEIN1 secretion and therefore cannot be the major cause of glucose's augmentation of Ca(2+)-induced PROTEIN2 secretion
523	These data indicate that an adequate level of GTP is critical for glucose's potentiation of Ca(2+)-induced PROTEIN1 secretion in primed islets but that PROTEIN2 activation can clearly be dissociated from PROTEIN secretion and therefore cannot be the major cause of glucose's augmentation of Ca(2+)-induced PROTEIN secretion
524	These data indicate that an adequate level of GTP is critical for glucose's potentiation of Ca(2+)-induced PROTEIN1 secretion in primed islets but that PROTEIN activation can clearly be dissociated from PROTEIN secretion and therefore cannot be the major cause of glucose's augmentation of Ca(2+)-induced PROTEIN2 secretion
525	These data indicate that an adequate level of GTP is critical for glucose's potentiation of Ca(2+)-induced PROTEIN secretion in primed islets but that PROTEIN1 activation can clearly be dissociated from PROTEIN secretion and therefore cannot be the major cause of glucose's augmentation of Ca(2+)-induced PROTEIN2 secretion
526	Regulation of PROTEIN1 secretion via ATP-sensitive K+ channel independent mechanisms: role of PROTEIN2 
527	The further addition of carbachol, an agonist that activates an isozyme of PROTEIN1 distinct from that activated by glucose, together with K+, 20 mM glucose, plus diazoxide resulted in a sustained amplification of PROTEIN2 secretion from mouse but not rat islets
528	The inability to activate a nutrient- and calcium-regulated PROTEIN1 isozyme in mouse islets to the same extent as in rat islets appears to account, at least in part, for these different PROTEIN2 secretory responses under these unique conditions
529	Further, the PROTEIN1 induced activation of IK(sl) was effectively antagonized by 5 x 10(-8) mol/l U-73122 or 5 x 10(-6) mol/l 2-nitro-4-carboxyphenyl N,N-diphenylcarbamate (inhibitors of the cell membrane phospholipase C), as well as by intracellularly applied heparin (selective inhibitor of PROTEIN2 (IP3)-induced Ca2+ release channels)
530	The data obtained suggest (i) that selective PROTEIN1 receptors are present on the membranes of guinea-pig antral smooth muscle cells, (ii) that the oxytocin-related relaxation may result from the activation of Ca(2+)-sensitive K+ conductivity via activation of PROTEIN2 induced release of Ca2+ from the submembrane located cisternae of the sarcoplasmic reticulum Ca2+ stores and (iii) in turn, this evokes a non-inactivating component of IK, hyperpolarizing the cell membrane
531	To elucidate the pathophysiologic significance of PROTEIN and PROTEIN in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN receptor defect, and investigated expression of the genes encoding PROTEIN1 and PROTEIN2 in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
532	To elucidate the pathophysiologic significance of PROTEIN1 and PROTEIN in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN receptor defect, and investigated expression of the genes encoding PROTEIN2 and PROTEIN in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
533	To elucidate the pathophysiologic significance of PROTEIN and PROTEIN in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN1 receptor defect, and investigated expression of the genes encoding PROTEIN2 and PROTEIN in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
534	To elucidate the pathophysiologic significance of PROTEIN and PROTEIN1 in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN receptor defect, and investigated expression of the genes encoding PROTEIN2 and PROTEIN in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
535	To elucidate the pathophysiologic significance of PROTEIN1 and PROTEIN in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN receptor defect, and investigated expression of the genes encoding PROTEIN and PROTEIN2 in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
536	To elucidate the pathophysiologic significance of PROTEIN and PROTEIN in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN1 receptor defect, and investigated expression of the genes encoding PROTEIN and PROTEIN2 in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
537	To elucidate the pathophysiologic significance of PROTEIN and PROTEIN1 in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN receptor defect, and investigated expression of the genes encoding PROTEIN and PROTEIN2 in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
538	To elucidate the pathophysiologic significance of PROTEIN1 and PROTEIN in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN2 receptor defect, and investigated expression of the genes encoding PROTEIN and PROTEIN in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
539	To elucidate the pathophysiologic significance of PROTEIN1 and PROTEIN2 in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN receptor defect, and investigated expression of the genes encoding PROTEIN and PROTEIN in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
540	To elucidate the pathophysiologic significance of PROTEIN and PROTEIN1 in the effect of TZDs on glucose metabolism and energy expenditure, we examined their basal mRNA levels in the WAT, brown adipose tissue (BAT), and skeletal muscle from Wistar fatty rats, a rat model of NIDDM and obesity with PROTEIN2 receptor defect, and investigated expression of the genes encoding PROTEIN and PROTEIN in Wistar fatty rats and in Wistar lean rats with 2-week oral administration of 3 mg x kg(-1) x day(-1) pioglitazone, a TZD derivative
541	These results clearly demonstrate that PROTEIN gene expression is upregulated by TZDs in the WAT and BAT in Wistar fatty rats, an obese model with PROTEIN1 receptor defect, and that adipose PROTEIN2 gene expression is increased in response to TZDs in vitro
542	These results clearly demonstrate that PROTEIN1 gene expression is upregulated by TZDs in the WAT and BAT in Wistar fatty rats, an obese model with PROTEIN2 receptor defect, and that adipose PROTEIN gene expression is increased in response to TZDs in vitro
543	These results clearly demonstrate that PROTEIN1 gene expression is upregulated by TZDs in the WAT and BAT in Wistar fatty rats, an obese model with PROTEIN receptor defect, and that adipose PROTEIN2 gene expression is increased in response to TZDs in vitro
544	Enhanced phosphoinositide hydrolysis via overexpression of PROTEIN1 beta1 or delta1 inhibits stimulus-induced PROTEIN2 release in insulinoma MIN6 cells.
545	To study the effects of enhanced phosphoinositide hydrolysis on PROTEIN1 secretion, phosphoinositide-specific PROTEIN (PLCbeta1) or PROTEIN2 was overexpressed in insulinoma MIN6 cells via adenoviral vectors.
546	To study the effects of enhanced phosphoinositide hydrolysis on PROTEIN secretion, phosphoinositide-specific PROTEIN1 (PLCbeta1) or PROTEIN2 was overexpressed in insulinoma MIN6 cells via adenoviral vectors.
547	To study the effects of enhanced phosphoinositide hydrolysis on PROTEIN1 secretion, phosphoinositide-specific PROTEIN2 (PLCbeta1) or PROTEIN was overexpressed in insulinoma MIN6 cells via adenoviral vectors.
548	Plasma PROTEIN1 and some functionally related peptides (CCK, gastrin, somatostatin and PROTEIN2 , were measured by standard radioimmunoassay techniques
549	The PROTEIN1 responsive elements conserved in cereal PROTEIN2 genes are not included in the 5'-upstream region of Rep1 or RepA
550	Tolbutamide and diazoxide modulate PROTEIN1 linked Ca(2+) signaling and PROTEIN2 secretion in beta-cells
551	We examined whether tolbutamide and diazoxide, which close or open ATP-sensitive K(+) channels (K(ATP) channels), respectively, interact with PROTEIN linked Ca(2+) signals in HIT-T15 and mouse beta-cells and with PROTEIN1 linked PROTEIN2 secretion from HIT-T15 cells
552	We examined whether tolbutamide and diazoxide, which close or open ATP-sensitive K(+) channels (K(ATP) channels), respectively, interact with PROTEIN1 linked Ca(2+) signals in HIT-T15 and mouse beta-cells and with PROTEIN linked PROTEIN2 secretion from HIT-T15 cells
553	We examined whether tolbutamide and diazoxide, which close or open ATP-sensitive K(+) channels (K(ATP) channels), respectively, interact with PROTEIN1 linked Ca(2+) signals in HIT-T15 and mouse beta-cells and with PROTEIN2 linked PROTEIN secretion from HIT-T15 cells
554	Thus tolbutamide and diazoxide regulate both PROTEIN1 linked Ca(2+) signaling and PROTEIN2 secretion from pancreatic beta-cells by modulating K(ATP) channels, thereby determining voltage-sensitive Ca(2+) influx
555	We examined for the first time in young men effects of intravenous injections of PROTEIN1 (4x50 or 100 microg, n = 9 and 11, respectively, at 22.00, 23.00, 24.00 and 01.00 compared to saline) on the sleep electroencephalogram (EEG; recorded from 23.00 to 07.00) and nocturnal secretion of adrenocorticotrophic hormone (ACTH), cortisol, growth hormone (GH), prolactin and PROTEIN2 
556	These results suggest that T3 may increase PROTEIN1 family expression independent of PROTEIN2 action
557	 PROTEIN1 effects on pulsatile gonadotropin releasing hormone secretion from the adult rat hypothalamus and interaction with cocaine and amphetamine regulated transcript peptide and PROTEIN2 [In Process Citation]
558	 PROTEIN1 may act as a negative feedback signal to the hypothalamic control of appetite through suppression of PROTEIN2 (NPY) secretion and stimulation of cocaine and amphetamine regulated transcript (CART).
559	We aimed at studying the effects of PROTEIN1 CART and PROTEIN2 on the hypothalamic control of the pituitary-gonadal system.
560	The increase in GnRH pulse amplitude caused by PROTEIN1 was totally prevented by coincubation with an anti-CART antiserum whereas it was not affected by coincubation with the PROTEIN2 Y5-receptor antagonist (10(-7) M).
561	In conclusion, PROTEIN1 and PROTEIN2 show separate permissive effects on GnRH secretion in the adult rat hypothalamus.
562	The induction of PROTEIN1 triggered by PROTEIN2 in barley embryos is repressed by sugars
563	Our results indicate that glucose represses PROTEIN1 signalling late along this hormone transduction pathway, downstream of transcription of the PROTEIN modulated transcriptional activator (GAMYB) needed for PROTEIN2 induction
564	Our results indicate that glucose represses PROTEIN signalling late along this hormone transduction pathway, downstream of transcription of the PROTEIN1 modulated transcriptional activator (GAMYB) needed for PROTEIN2 induction
565	Our results indicate that glucose represses PROTEIN1 signalling late along this hormone transduction pathway, downstream of transcription of the PROTEIN2 modulated transcriptional activator (GAMYB) needed for PROTEIN induction
566	The results demonstrate that potent antioxidants, such as PROTEIN1 protect MM-LDL from lipoperoxidation and preserve their ability to efficiently deliver PROTEIN2 to cells
567	Constitutive expression of PKABA1 drastically suppressed expression of low- and high-pI PROTEIN1 and protease genes induced by PROTEIN2 
568	Long-term changes in gastrin, cholecystokinin and PROTEIN1 in response to PROTEIN2 treatment
569	The present study was designed to investigate how repeated injections of PROTEIN1 influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), PROTEIN and somatostatin, as well as of endogenous PROTEIN2 and glucose
570	The present study was designed to investigate how repeated injections of PROTEIN influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), PROTEIN1 and somatostatin, as well as of endogenous PROTEIN2 and glucose
571	The present study was designed to investigate how repeated injections of PROTEIN1 influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), PROTEIN2 and somatostatin, as well as of endogenous PROTEIN and glucose
572	In addition, both PROTEIN1 and CCK levels were decreased in response to the PROTEIN2 treatment when measured 3 and 10 days after the last injection (ANOVA; PROTEIN p < 0.01, CCK p < 0.05)
573	In addition, both PROTEIN1 and CCK levels were decreased in response to the PROTEIN treatment when measured 3 and 10 days after the last injection (ANOVA; PROTEIN2 p < 0.01, CCK p < 0.05)
574	In addition, both PROTEIN and CCK levels were decreased in response to the PROTEIN1 treatment when measured 3 and 10 days after the last injection (ANOVA; PROTEIN2 p < 0.01, CCK p < 0.05)
575	When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with PROTEIN1 or saline, plasma levels of PROTEIN and CCK increased significantly (p < 0.05) in the PROTEIN2 treated rats, when compared to saline-treated controls receiving clonidine only
576	When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with PROTEIN or saline, plasma levels of PROTEIN1 and CCK increased significantly (p < 0.05) in the PROTEIN2 treated rats, when compared to saline-treated controls receiving clonidine only
577	When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with PROTEIN1 or saline, plasma levels of PROTEIN2 and CCK increased significantly (p < 0.05) in the PROTEIN treated rats, when compared to saline-treated controls receiving clonidine only
578	In conclusion, these results show that PROTEIN1 induces long-lasting changes in plasma levels of gastrin, CCK and PROTEIN2 without affecting somatostatin or glucose levels
579	Our data demonstrate, that activation of mitogen activated protein (MAP) kinase alone is sufficient to promote PROTEIN1 secretion, whereas inhibition of MAP kinase will reduce PROTEIN secretion only when PROTEIN2 or phosphatidylinositol 3-kinase are additionally inhibited
580	Our data demonstrate, that activation of mitogen activated protein (MAP) kinase alone is sufficient to promote PROTEIN secretion, whereas inhibition of MAP kinase will reduce PROTEIN1 secretion only when PROTEIN2 or phosphatidylinositol 3-kinase are additionally inhibited
581	Our data demonstrate, that activation of mitogen activated protein (MAP) kinase alone is sufficient to promote PROTEIN1 secretion, whereas inhibition of MAP kinase will reduce PROTEIN2 secretion only when PROTEIN or phosphatidylinositol 3-kinase are additionally inhibited
